Viking Therapeutics Initiates SUNRISE Phase 3 Clinical Program For Oral VK2735 Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors
VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.The SUNRISE Phase 3 program includes two studies evaluating oral VK2735:
Viking Therapeutics started big testing of a new obesity pill. When a company reaches this testing stage, it shows real progress toward a real product.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.